Sarepta Therapeutics at a Regulatory Crossroads

Sarepta Therapeutics re-evaluates clinical data to secure full FDA approval for Amondys 45 and Vyondys 53, while projecting strong future sales for its gene therapy ELEVIDYS.

Sarepta Therapeutics finds itself navigating a critical juncture in its relationship with the U.S. Food and Drug Administration (FDA). The biopharmaceutical firm is engaged in a pivotal effort to secure long-term market approval for its core therapies, following a period of mixed clinical trial outcomes. The company's strategy hinges on a comprehensive statistical re-evaluation of existing data to persuade regulators.

Commercial Momentum Amidst Leadership Transition

On the commercial front, Sarepta continues to advance the global rollout of its gene therapy, ELEVIDYS, which launched in Japan last month. Management has provided a revenue forecast for the 2026 fiscal year, projecting product sales to land between $1.2 billion and $1.4 billion. This guidance follows the company's expectations for 2025.

Seeking Validation Through Post-Hoc Analysis

The immediate regulatory focus centers on the therapies Amondys 45 and Vyondys 53. While the topline results from the pivotal Phase 3 ESSENCE study failed to meet statistical significance for its primary endpoint, Sarepta is banking on a detailed post-hoc analysis. The company argues that when data from participants affected by the pandemic are excluded, the results demonstrate a clinically meaningful slowing of disease progression.

Sarepta is leveraging these findings in ongoing discussions with the FDA. The objective is to convert the existing accelerated approvals for these treatments into full, traditional approvals. Updated long-term data supporting this case were presented yesterday at the MDA clinical conference.

The coming months will be decisive for Sarepta as it works to align its clinical evidence with regulatory standards and solidify the commercial future of its key products.